When the FDA put a black box warning on tofacitinib in 2021, the message was blunt: more heart attacks, more cancers, and more blood clots. The warning came from the ORAL Surveillance trial, which followed over 4,000 patients with rheumatoid arthritis already at high cardiovascular risk. Compared to TNF blockers, patients on tofacitinib had: Heart
Tofacitinib: a lesson in heart-immune health originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.